RxDoctor Payments Data

Chockalingam Narayanan, MD

Clinical Cardiac Electrophysiology · Galveston, TXNPI 1508276296

Payments from drug & device makers

$32,233in general payments, 2019–2025

Across 275 payments — averaging $117.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$18K
  • Medtronic$9K
  • Abbott$4K
  • Biosense Webster, Inc.$601
  • Impulse Dynamics (USA) Inc.$222
  • AstraZeneca$100
  • plus $87 from 1 others

What the payments were for

  • Speaking & faculty fees$11,70036%
  • Grants$8,66727%
  • Travel & lodging$4,13813%
  • Food & beverage$6,56420%
  • Education$1,1644%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific180$18,177
Medtronic11$8,964
Abbott43$4,082
Biosense Webster, Inc.34$601
Impulse Dynamics (USA) Inc.2$222
AstraZeneca1$100
Pfizer4$87

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,233 in reported general payments places this provider in the 45th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$175,452
Medicare patients
513
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$346,510
XareltoRivaroxaban24$14,716
Dofetilide20$7,983
Amiodarone Hcl110$3,448
Metoprolol Succinate145$2,449
Flecainide Acetate42$1,630
Mexiletine Hcl19$825
SotalolSotalol Hcl17$799
Metoprolol Tartrate122$736
ClopidogrelClopidogrel Bisulfate40$390
Atorvastatin Calcium43$320
Dilt-XrDiltiazem Hcl12$253
Lisinopril40$246
Amlodipine Besylate38$202
Diltiazem 24hr Er (Xr)Diltiazem Hcl12$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$346,510409 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →